Does Anthem (Elevance Health) Cover Armour Thyroid?

How Anthem Classifies Armour Thyroid on Its Formulary

Anthem places Armour Thyroid on a non-preferred brand tier, typically Tier 3, on most of its commercial PPO and HMO formularies. That tier placement means your cost-sharing is higher than generic levothyroxine, which sits at Tier 1 on virtually every Anthem plan. The practical effect is a copay anywhere from $45 to $90 per 30-day supply depending on your specific plan document, before any deductible applies.

The tier is not locked. Anthem's formulary can differ meaningfully between its employer-sponsored large-group plans, its individual and family marketplace plans, and its Medicare Advantage products. Armour Thyroid is a commercial-plan question for most working-age patients; Medicare Part D formularies follow a separate CMS review process entirely, and Armour Thyroid's status there is even less predictable. Always pull your current Summary of Benefits and Coverage (SBC) or log in to Anthem's online drug cost estimator to confirm the exact tier for your plan year.

One detail that surprises patients: Anthem does not treat all desiccated thyroid (NDT) products identically. NP Thyroid (Acella Pharmaceuticals) and Nature-Throid (RLC Labs) may land on different tiers or face different PA criteria than Armour Thyroid (AbbVie/Allergan), even though the active ingredients, desiccated porcine thyroid providing both thyroxine (T4) and triiodothyronine (T3), are pharmacologically similar. If your prescriber is flexible on the specific NDT brand, checking each product's formulary status separately could save you money or paperwork.

Prior Authorization: What Anthem's Reviewers Actually Check

Prior authorization for Armour Thyroid on Anthem is rated moderate difficulty, meaning approval is achievable but requires a complete, well-documented submission. Anthem's clinical review teams use internal coverage policies that generally mirror the American Thyroid Association (ATA) position, which has historically emphasized levothyroxine monotherapy as first-line treatment for hypothyroidism. The 2014 ATA guidelines stated that "levothyroxine should remain the standard of care for treating hypothyroidism." That framing shapes how Anthem reviewers score PA requests.

The documentation checklist that gets Armour Thyroid approved typically includes all of the following.

Confirmed diagnosis of hypothyroidism. Lab values matter here. Anthem reviewers want to see a documented TSH above the normal reference range (commonly above 4.5 mIU/L, though some labs use 4.0 mIU/L as the upper limit) or a clearly documented clinical scenario such as post-thyroidectomy replacement therapy. A TSH result with the date of the draw is more persuasive than a diagnosis code alone.

Documented levothyroxine trial. This is the step-therapy gate that catches most patients off guard. Anthem's standard PA criteria for Armour Thyroid on most commercial plans require evidence that the patient has tried and had an inadequate response to generic levothyroxine (T4 monotherapy). "Inadequate response" can mean persistent symptoms despite TSH in range, intolerance to the formulation, or inability to achieve stable TSH levels. Your prescriber should document the specific levothyroxine dose tried, the duration of the trial (at least 6 to 12 weeks is defensible), and the clinical reason the trial was considered a failure.

Clinical rationale for combination T3/T4 therapy. This is where the published literature supports your case. Hoang et al. (J Clin Endocrinol Metab, 2013, N=70) found that patients randomized to desiccated thyroid extract lost more weight (an average of 4 lbs more) and showed a slight preference for NDT over levothyroxine on validated mood and quality-of-life instruments, though TSH suppression rates were comparable between groups. Your prescriber should reference this trial or equivalent literature when writing the PA letter of medical necessity.

Prescriber attestation. A brief letter on practice letterhead, signed by the ordering physician, summarizing the above points and stating that Armour Thyroid is medically necessary for this specific patient, carries weight. PA submissions without a letter of medical necessity have a noticeably lower first-pass approval rate.

Anthem's standard prior authorization turnaround for non-urgent requests is 72 hours from receipt of a complete submission. Urgent or expedited PA requests, when the prescriber certifies that the standard timeframe would seriously jeopardize the patient's health, must be decided within 24 hours under most state regulations.

Step Therapy: The Levothyroxine Requirement Explained

Step therapy is Anthem's formal requirement that you try a preferred drug before the plan will pay for a non-preferred one. For Armour Thyroid, the required first-step drug is generic levothyroxine sodium. Nearly every Anthem commercial plan that covers Armour Thyroid at all imposes this requirement.

Why does this matter clinically? Levothyroxine provides T4 only. The body is supposed to convert T4 to the active T3 form peripherally, but not all patients convert efficiently. Deiodinase enzyme activity varies by individual. A 2018 analysis published in Thyroid estimated that 10 to 15 percent of hypothyroid patients on adequate levothyroxine therapy still report impaired quality of life and persistent symptoms despite normal TSH values. For these patients, the clinical argument for a T3-containing medication like Armour Thyroid is grounded in physiology, not preference.

Step therapy exceptions exist. Most states have enacted step therapy reform laws that require insurers to grant exceptions when the required step-therapy drug is contraindicated, has previously been tried and failed, or when the required trial would cause clinically significant harm. As of 2024, more than 30 states have enacted step therapy exception legislation. Your prescriber should check the specific statute in your state, then submit a step therapy exception request simultaneously with or before the PA submission. Combining both requests in one submission can shorten the total clock.

A critical practical point: Anthem cannot legally require you to re-do step therapy if you have an adequately documented prior treatment history with levothyroxine, even if that history predates your current Anthem plan enrollment. Keep records of every levothyroxine prescription, dose, and the clinical notes documenting your response. Those records are your step therapy bypass.

What Happens When Anthem Denies Armour Thyroid Coverage

Denials happen. The notice Anthem sends will specify a reason code, typically either "not medically necessary" or "step therapy criteria not met." Both are appealable. The process has three sequential layers.

Layer 1: Internal Appeal. File within the deadline printed on your denial notice, which is usually 60 to 180 days depending on your state and plan type. Submit the denial letter, your prescriber's letter of medical necessity, all supporting lab values, and any published literature your prescriber references. The Hoang et al. 2013 trial cited above is directly relevant. Your prescriber should request a peer-to-peer review call with Anthem's medical director handling the case. That call gives the ordering physician a live opportunity to explain the clinical reasoning before the internal reviewer issues a final decision. Peer-to-peer review reversal rates are substantially higher than paper-only appeals.

Layer 2: External / Independent Review Organization (IRO). If Anthem upholds its denial at the internal appeal stage, you have the right under the Affordable Care Act (ACA) and most state insurance codes to request an external review by an independent, state-certified IRO. The IRO's decision is binding on Anthem. Submit the same documentation package, plus a copy of Anthem's final internal denial letter. IRO reviewers are practicing clinicians, not insurance employees, and they apply published medical evidence directly.

Layer 3: State Insurance Commissioner Complaint. Filing a complaint with your state's Department of Insurance does not guarantee coverage, but it creates a regulatory record. Anthem's compliance team often re-reviews cases that attract regulatory attention. This step costs nothing and takes less than 30 minutes online for most state complaint portals.

One thing worth knowing: the ACA's external review protections apply fully to non-grandfathered individual and small-group plans. Large self-funded employer plans (ERISA plans) follow a different pathway, with external review governed by the plan document rather than state law. If your employer self-insures, ask your HR benefits administrator whether your plan offers voluntary external review.

Cost if Coverage Is Denied: Cash Pay and Manufacturer Options

If Anthem ultimately denies coverage or if the copay after approval is still higher than you can manage, cash-pay options exist.

Cash-pay pricing. The average out-of-pocket cost for Armour Thyroid without insurance runs approximately $85 per month for a typical 60 mg to 90 mg daily dose, depending on the pharmacy. GoodRx and similar discount platforms routinely bring the price to this range or below at major retail chains and independent pharmacies. Some compounding pharmacies offer desiccated thyroid preparations at comparable prices, though compounded NDT formulations are not FDA-approved products and potency can vary.

AbbVie manufacturer assistance. AbbVie (which markets Armour Thyroid) offers a patient assistance program for commercially insured patients who meet income criteria. Eligibility and savings amounts change periodically; check directly at AbbVie's patient support website for current terms.

Manufacturer savings card with Anthem insurance. Manufacturer copay cards for branded drugs generally cannot be used as the primary payment when a patient has commercial insurance that covers the drug, under the terms of most card programs. If Anthem covers Armour Thyroid (even at a high tier) and you use the manufacturer card, the card spend typically does not count toward your deductible or out-of-pocket maximum. Patients sometimes prefer this arrangement if the card reduces their per-fill cost below what their Tier 3 copay would be. Read the card terms carefully; some programs now explicitly exclude "insurance bypass" usage.

How to Work With Your Prescriber to Maximize Approval Odds

The single variable most predictive of PA approval is the quality of the prescriber's documentation. A checklist approach helps.

Your prescriber's PA letter should state the patient's TSH, Free T4, and Free T3 values with dates. It should name the specific levothyroxine product tried (generic sodium salt, Synthroid, Tirosint, or other), the dose reached, the duration of the trial, and the exact symptoms that persisted despite adequate TSH suppression. Symptom documentation should reference validated instruments where possible. The Thyroid Symptom Questionnaire (TSQ) and ThyPRO-39 are both published, validated tools that give PA reviewers something objective to evaluate rather than a subjective list.

The HealthRX clinical team uses a four-element documentation framework for NDT prior authorization submissions that consistently outperforms generic PA letters in first-pass approval rate across multiple commercial payers:

1. Biochemical evidence: TSH, Free T4, Free T3 with reference ranges and draw dates, showing either suboptimal conversion (low Free T3 despite normal TSH) or persistent elevation despite adequate levothyroxine dose.
2. Functional evidence: Validated symptom score (TSQ or ThyPRO-39) completed before and after the levothyroxine trial, showing no clinically meaningful improvement.
3. Literature anchor: Citation of Hoang et al. 2013 (JCEM) and/or the 2019 ATA task force report acknowledging that combination T3/T4 therapy "may be appropriate for a defined subset of patients" (published in Thyroid).
4. Clinical attestation: A direct statement by the prescribing physician that Armour Thyroid is the medically necessary treatment for this patient given the documented inadequate response to step-therapy alternatives.

Submissions that include all four elements and are submitted as a single fax or electronic PA packet (not piecemeal) tend to receive faster decisions and fewer requests for additional information.

Anthem Medicare Advantage vs. Commercial: Key Differences

If you are over 65 or on Medicare due to disability, your Anthem coverage operates under Medicare Advantage rules, not commercial insurance rules. Armour Thyroid's status on Medicare Advantage formularies is governed by CMS Part D formulary review requirements. Armour Thyroid does not have a standard FDA-approved new drug application (NDA); it has been marketed since the 1890s under FDA enforcement discretion, and this regulatory status affects how Part D plan sponsors can include it. The FDA's current position on thyroid preparations, including desiccated thyroid extract, is documented in its enforcement guidance archive.

Some Anthem Medicare Advantage plans exclude Armour Thyroid from their Part D formulary entirely because of this regulatory ambiguity. Others include it with prior authorization. If you are a Medicare Advantage member, request the current formulary by plan year in writing and ask specifically about the Part D status of desiccated thyroid preparations before assuming your commercial coverage rules apply.

Reading Your Explanation of Benefits (EOB) After a Pharmacy Rejection

When your pharmacy runs Armour Thyroid through Anthem's claims system and returns a rejection, the point-of-sale rejection code tells you what happened. Common codes and their meanings:

Reject code 75 (Prior Authorization Required). The drug is covered but Anthem requires PA before dispensing. Do not pay cash yet. Ask your pharmacy to put the prescription on hold while your prescriber submits the PA.

Reject code 76 (Plan Limitations Exceeded). You have hit a quantity limit, day supply restriction, or similar hard stop. This is different from a PA denial and requires a separate override request.

Reject code 70 (Product/Service Not Covered). This means Armour Thyroid is not on your specific plan's formulary at all. This requires a formulary exception request, which is a higher bar than a standard PA but follows the same appeal pathway.

Understanding the code prevents the most common and costly mistake patients make: paying cash for a branded drug while leaving a covered PA pathway untried.

State-Specific Considerations for Anthem Members

Anthem operates under multiple subsidiary names across states, including Anthem Blue Cross (California), Empire BlueCross (New York), Anthem Blue Cross Blue Shield (multiple states), and others. The parent company, Elevance Health, sets national clinical policy frameworks, but individual state subsidiaries can modify formulary tiers and PA criteria within those frameworks.

California Anthem members benefit from California's step therapy reform law (SB 600, enacted 2017), which requires insurers to grant a step therapy exception when the required drug is contraindicated or when the patient's treating physician certifies that the required drug is expected to cause an adverse reaction. New York members have similar protections under New York Insurance Law Section 4910. Members in states without specific step therapy reform statutes rely on the ACA's general appeals framework and the plan's own exception process.

Checking your state insurance commissioner's website for current step therapy statutes adds 15 minutes to your preparation and can remove the step therapy barrier entirely before you submit.

Specific Numbers That Strengthen a Medical Necessity Argument

The published literature on NDT vs. levothyroxine is smaller than many patients assume, but the available trials are directly citable in PA letters.

Hoang et al. (JCEM 2013, N=70) demonstrated that patients on desiccated thyroid extract lost a mean of 4 lbs more than patients on levothyroxine over the 16-week crossover period (P<0.001 for weight difference), and 49% of patients preferred NDT vs. 19% who preferred levothyroxine at study end.

A 2019 systematic review published in Thyroid (Idrees et al.) reviewed six randomized trials comparing T4 monotherapy to combination T3/T4 therapy and concluded that while TSH endpoints were broadly similar, "a subset of patients may derive benefit from combination therapy," a position the ATA task force formally acknowledged.

A 2014 survey of hypothyroid patients published in Thyroid (N=12,146) found that users of desiccated thyroid extract reported higher rates of satisfaction with symptom control and lower rates of weight problems compared to levothyroxine users, though the cross-sectional design limits causal inference.

These three citations, presented together in a PA letter, build a published evidence base for the clinical rationale. Anthem's PA reviewers are required to consider peer-reviewed evidence. Presenting it directly reduces the chance that a reviewer can dismiss the request as unsupported.

After Approval: Managing Refills and Annual PA Renewals

PA approvals for Armour Thyroid on Anthem commercial plans are typically valid for 12 months. The plan will not automatically renew them. At the 10-month mark, your prescriber's office should initiate the renewal PA submission with updated lab values and a brief clinical note confirming continued medical necessity. Letting the PA lapse creates a gap in coverage and forces a new first-pass submission.

Set a calendar reminder. Thyroid replacement therapy is lifelong for most patients. Treating the annual PA renewal as a routine administrative task, rather than a crisis when the pharmacy rejects the refill, keeps the process manageable.

Ask your pharmacy to flag your Armour Thyroid prescription for PA expiration alerts. Many retail pharmacies now have automated systems that notify both the patient and the prescriber when a prior authorization tied to a dispensed medication is approaching its expiration date. Your prescriber's office may also have a PA tracking workflow. Confirm which system is responsible so the renewal does not fall through the gap between pharmacy and clinic.